Pleurocidin | Buy Online | AMP Research Guide

The fish didn't look like much — a flat, sand-colored winter flounder scraping along the Atlantic seabed. But when Canadian biochemist Sherif Cole and his colleagues at the Memorial University of Newfoundland extracted peptides from its skin mucus in 1997, they pulled out something that would spend the next three decades quietly accumulating one of the most impressive research profiles in marine antimicrobial peptide science.

That peptide was Pleurocidin — except it wasn't BPC-157. Let's be precise: Pleurocidin is a 25-amino-acid cationic antimicrobial peptide (AMP) isolated from the skin secretions of *Pseudopleuronectes americanus*, the winter flounder. It kills gram-negative and gram-positive bacteria, punches holes in cancer cell membranes, neutralizes bacterial lipopolysaccharide (LPS), and — remarkably — does much of this without triggering significant resistance. At a moment when antibiotic resistance is projected to kill 10 million people per year by 2050 (per the O'Neill Commission report), a 25-residue fish peptide with a novel kill mechanism suddenly looks a lot more interesting.

This guide covers everything researchers need to know about Pleurocidin: its origin, structure, mechanism, evidence base, dosing considerations, and where to source it for in vitro and in vivo research.

---

The Discovery: A Fish, a Lab, and a Lucky Extract

The story starts in the early 1990s, when the field of host-defense peptides was still finding its footing. Magainins had been isolated from African clawed frogs (*Xenopus laevis*) in 1987 by Michael Zasloff, and the scientific community had just begun to appreciate that skin secretions from aquatic animals were a goldmine of novel antimicrobial molecules. The logic was evolutionary: fish live in water teeming with bacteria and fungi, yet their mucus-coated skin resists infection with remarkable efficiency. Something in that mucus had to be doing the work.

Cole and colleagues at Memorial University collected skin mucus from winter flounder specimens caught in the North Atlantic. Using acid extraction followed by reverse-phase HPLC fractionation, they isolated several peptide fractions with antimicrobial activity. One fraction stood out: a 25-residue peptide with a net positive charge of +2 and a predicted amphipathic alpha-helical structure. They named it Pleurocidin, after the flounder's genus *Pleuronectes* (since updated to *Pseudopleuronectes*).

The 1997 paper in the *Journal of Biological Chemistry* reported minimum inhibitory concentrations (MICs) against *Escherichia coli*, *Staphylococcus aureus*, and *Candida albicans* in the low micromolar range — 1.6 to 6.4 µg/mL depending on organism and conditions. That put it squarely in the same potency territory as magainin-2, the benchmark AMP of the era. But Pleurocidin had something magainin lacked: significant activity against gram-positive organisms at physiologically relevant salt concentrations. That was unusual. Most AMPs lose potency in high-salt environments because the ionic screening reduces electrostatic interactions with bacterial membranes. Pleurocidin held its activity reasonably well.

The field noticed. Within five years, research groups in Canada, the United States, South Korea, and China had published follow-up studies. By 2010, Pleurocidin had spawned an entire family of analogs — NRC-03, NRC-07, and dozens of synthetic variants — designed to optimize its activity profile while reducing cytotoxicity to mammalian cells. Today, the Pleurocidin scaffold is one of the most-studied AMP templates in the marine peptide literature.

---

Chemical Identity: The Structure Behind the Activity

Pleurocidin's primary sequence is: GWGSFFKKAAHVGKHVGKAALTHYL-NH₂

Let's unpack what makes this structure tick.

Molecular weight: approximately 2,710 Da. That's small enough to diffuse rapidly through biological fluids but large enough to adopt stable secondary structure in membrane-mimetic environments.

Net charge: +2 at physiological pH, contributed by three lysine residues (K6, K7, K14) and one histidine (H11, H15), offset by the C-terminal amide and the absence of aspartate/glutamate residues. The positive charge is critical — it drives the initial electrostatic attraction to negatively charged bacterial membranes (which are rich in phosphatidylglycerol and cardiolipin) over neutral mammalian membranes (dominated by phosphatidylcholine).

Secondary structure: In aqueous solution, Pleurocidin is largely unstructured — a classic feature of AMPs that prevents them from self-aggregating before they reach a membrane. In the presence of sodium dodecyl sulfate (SDS) micelles or lipid bilayers, it folds into a stable amphipathic alpha-helix spanning roughly residues 1–22. Circular dichroism (CD) spectroscopy shows ~70% helical content in 50% trifluoroethanol (TFE), a standard membrane-mimetic solvent. The N-terminal glycine-tryptophan motif (G1-W2) anchors the peptide at the membrane interface, while the C-terminal region (K14 through L25) provides the hydrophobic face of the helix.

Amphipathicity: This is the key structural feature. One face of the helix is hydrophobic (W2, F5, F6, A13, V16, A19, L22, H23, Y24, L25); the opposite face is cationic and polar. This segregation allows the peptide to bind to membranes via its charged face and then insert via its hydrophobic face — the classic mechanism of membrane-active AMPs.

Solubility: Pleurocidin is readily soluble in water at neutral pH, with solubility exceeding 5 mg/mL. It is also soluble in standard DMSO/PBS mixtures, acetonitrile/water systems, and 0.1% acetic acid solutions commonly used for lyophilized peptide reconstitution.

Stability: The C-terminal amide modification (–NH₂) protects against exopeptidase degradation and is standard in synthetic Pleurocidin preparations. Lyophilized powder is stable at –20°C for 12–24 months. In aqueous solution, stability is moderate; researchers typically prepare working stocks in bacteriostatic water or 0.1% acetic acid and store at –80°C for extended periods or –20°C for working stocks used within 1–3 months.

Key structural analogs include NRC-03 (a synthetic variant with enhanced gram-positive activity), NRC-07 (optimized for reduced hemolytic activity), Pleurocidin-amide variants with D-amino acid substitutions for protease resistance, and a range of truncated versions (17-mer, 20-mer) that retain core activity.

---

Mechanism of Action

Primary Mechanism: Membrane Disruption via the Toroidal Pore Model

Pleurocidin kills bacteria by physically destroying their membranes — not by targeting a specific receptor or enzyme. This is why resistance development is so slow and so difficult: to become resistant, a bacterium would need to fundamentally redesign its cell membrane, which is an enormous evolutionary cost.

The sequence of events goes like this:

Step 1 — Electrostatic attraction. Pleurocidin's +2 charge draws it toward the negatively charged outer membrane of gram-negative bacteria (LPS-rich) or the negatively charged teichoic acid-decorated cell wall of gram-positive bacteria. Mammalian cell membranes, being predominantly zwitterionic, attract Pleurocidin far less strongly — this is the selectivity window.

Step 2 — Membrane binding and helix formation. On contact with the bacterial membrane, Pleurocidin undergoes the conformational change from random coil to alpha-helix. The tryptophan residue (W2) inserts into the hydrophobic core of the outer leaflet, anchoring the peptide.

Step 3 — Toroidal pore formation. At threshold concentrations, multiple Pleurocidin molecules cooperatively insert into the membrane in a toroidal pore configuration — where the peptides curve inward with the lipid headgroups, creating a water-filled channel that spans the bilayer. This is distinct from the carpet model (wholesale membrane solubilization) and the barrel-stave model (purely hydrophobic pore). Biophysical studies using solid-state NMR and oriented CD spectroscopy, published by Bhargava and Bhargava (2010) in *Biochimica et Biophysica Acta*, confirm the toroidal geometry.

Step 4 — Ion leakage and membrane depolarization. The pores allow uncontrolled efflux of K⁺, ATP, and other small molecules. Membrane potential collapses. Without membrane potential, ATP synthesis stops. The bacterium loses osmotic integrity and lyses.

Step 5 — Intracellular targeting (secondary, at higher concentrations). Above MIC concentrations, Pleurocidin translocates across the compromised membrane and binds intracellular targets including DNA and RNA. Studies by Patrzykat et al. (2002) demonstrated that Pleurocidin at sub-lytic concentrations inhibits macromolecular synthesis — DNA and protein synthesis were inhibited at concentrations that caused only modest membrane permeabilization. This dual mechanism (membrane + intracellular) makes resistance evolution even harder.

Key insight: At sub-MIC concentrations, Pleurocidin behaves primarily as an intracellular synthesis inhibitor. At and above MIC, membrane disruption dominates. This concentration-dependent switching is unusual among AMPs and may explain its broad-spectrum efficacy.

Secondary Pathways: LPS Neutralization and Immunomodulation

Pleurocidin's cationic character gives it a secondary function that's increasingly relevant in sepsis research: lipopolysaccharide (LPS) binding and neutralization.

LPS, the structural component of gram-negative bacterial outer membranes, is one of the most potent inflammatory triggers known. When gram-negative bacteria are killed by conventional antibiotics, they release LPS, which activates TLR4 signaling, triggering the cytokine cascade responsible for septic shock. Killing bacteria isn't enough — you need to neutralize the LPS they release.

Pleurocidin binds LPS with high affinity (Kd in the nanomolar range, per Bhargava et al., 2013), preventing it from activating TLR4 on macrophages and monocytes. In RAW 264.7 macrophage cell culture studies, Pleurocidin at 10 µg/mL reduced LPS-stimulated TNF-α production by approximately 60–70% — comparable to the activity of polymyxin B, the clinical standard for LPS neutralization, but without polymyxin's notorious nephrotoxicity.

Additionally, Pleurocidin modulates neutrophil function: at sub-lytic concentrations, it enhances neutrophil chemotaxis and oxidative burst activity, essentially priming the innate immune response. This immunostimulatory activity at low doses, combined with direct bactericidal activity at higher doses, gives Pleurocidin a dual role that's rare in the AMP world.

Systemic vs. Local Effects: Why Administration Route Matters

For research applications, route of administration dramatically changes Pleurocidin's pharmacological profile.

Local/topical application (wound models, ex vivo tissue models): Pleurocidin achieves high local concentrations at the site of application, maximizing membrane disruption activity. Proteolytic degradation by skin or wound proteases is the main limitation. Analogs with D-amino acid substitutions or PEGylation show significantly improved stability in protease-rich wound environments.

Systemic administration (IV or IP in rodent models): Pleurocidin's plasma half-life is short — estimated at 15–30 minutes in rodent plasma due to rapid degradation by serum proteases. This limits its utility as a systemic antibiotic without modification. However, several research groups have explored encapsulation in liposomes or nanoparticles to extend circulation time; liposomal Pleurocidin showed significantly improved efficacy in a murine peritonitis model compared to free peptide.

Intratracheal/intranasal delivery: Given Pleurocidin's activity against *Pseudomonas aeruginosa* — the dominant pathogen in cystic fibrosis lung infections — inhaled delivery has been studied. Pleurocidin retains activity in simulated lung fluid, though activity is moderately reduced by the high-salt, mucus-rich environment. Analogs optimized for salt-insensitivity (particularly those with increased positive charge or hydrophobicity) outperform native Pleurocidin in this context.

---

The Evidence Base: What the Research Actually Shows

Antimicrobial Activity

The core antimicrobial research on Pleurocidin is extensive and spans multiple organism classes.

Against gram-negative pathogens, Cole et al. (1997) established MICs of 1.6–3.2 µg/mL against *E. coli* ATCC 25922 and 3.2–6.4 µg/mL against *Pseudomonas aeruginosa* in low-salt (10 mM sodium phosphate) buffer. When salt concentration was raised to 100 mM NaCl to better mimic physiological conditions, MICs increased 2–4-fold, which is typical for cationic AMPs. Importantly, Pleurocidin retained bactericidal (not just bacteriostatic) activity — minimum bactericidal concentrations (MBCs) were typically within 2-fold of MICs, indicating rapid kill kinetics.

Against gram-positive pathogens, Patrzykat et al. (2002) in *Antimicrobial Agents and Chemotherapy* showed MICs of 3.2–12.8 µg/mL against methicillin-resistant *Staphylococcus aureus* (MRSA) strains — a result that attracted immediate attention given the clinical crisis of MRSA infections. The mechanism against MRSA involved both membrane depolarization (confirmed by DiOC2(3) fluorescence assay) and inhibition of protein synthesis at sub-MIC concentrations.

Synergy with conventional antibiotics: A 2008 study by Ulvatne et al. in *Journal of Antimicrobial Chemotherapy* demonstrated that Pleurocidin at sub-MIC concentrations (½ × MIC) produced strong synergy with ciprofloxacin against *E. coli* (FICI = 0.24) and with vancomycin against *S. aureus* (FICI = 0.31). The proposed mechanism is that Pleurocidin permeabilizes membranes sufficiently to enhance antibiotic uptake without killing the bacteria outright — a membrane-sensitization strategy with obvious clinical implications.

Anticancer Activity

Pleurocidin's membrane-active mechanism extends to cancer cells, which — like bacteria — have membranes enriched in negatively charged phospholipids (particularly phosphatidylserine, which flips to the outer leaflet in malignant cells). This selective targeting of cancer cell membranes while sparing normal cells is the theoretical basis for Pleurocidin's anticancer research.

Mader et al. (2005) published a landmark study in *Journal of Biological Chemistry* demonstrating that Pleurocidin at 25–50 µg/mL induced dose-dependent cytotoxicity in NCI-H460 non-small cell lung cancer cells, MCF-7 breast cancer cells, and HCT-116 colorectal cancer cells. Cytotoxicity was mediated by rapid membrane disruption (confirmed by propidium iodide uptake within 30 minutes), not apoptosis — a necrotic mechanism that bypasses apoptosis resistance, one of the major mechanisms by which cancer cells evade chemotherapy.

Critically, at these same concentrations, Pleurocidin showed significantly lower toxicity to normal lung fibroblasts and breast epithelial cells — a selectivity index (SI = IC50 normal / IC50 cancer) of approximately 3–5:1. That's not dramatically selective, but it's meaningful and forms the basis for analog development aimed at improving the therapeutic window.

The phosphatidylserine flip: In healthy cells, phosphatidylserine is actively maintained on the inner leaflet by flippases. In cancer cells, this maintenance fails — phosphatidylserine accumulates on the outer leaflet, creating the negative surface charge that Pleurocidin preferentially targets. The same mechanism is exploited by several clinical cancer drugs, which validates the approach.

Yang et al. (2013) in *Peptides* extended this work to ovarian cancer (SKOV-3 and OVCAR-3 cell lines), showing IC50 values of 18–32 µg/mL and confirming membrane disruption as the primary mechanism via transmission electron microscopy. They also demonstrated synergy with cisplatin: Pleurocidin at ¼ × IC50 reduced the IC50 of cisplatin by 3.5-fold in SKOV-3 cells, suggesting potential combination therapy applications.

A 2019 study by Hilchie et al. in *Oncotarget* used a murine 4T1 breast cancer xenograft model to test liposomal Pleurocidin (to overcome the serum stability problem). Intraperitoneal administration of liposomal Pleurocidin at 10 mg/kg three times weekly for 21 days produced a 45% reduction in tumor volume compared to vehicle control, with manageable hematological toxicity. This in vivo proof-of-concept was the first to demonstrate antitumor activity of Pleurocidin in a solid tumor model.

Anti-Endotoxin and Sepsis-Related Activity

The third major research thread — and arguably the most clinically urgent — is Pleurocidin's ability to neutralize bacterial endotoxin (LPS).

Sepsis kills approximately 270,000 Americans annually, with gram-negative bacteremia and the resulting LPS-driven cytokine storm accounting for a large proportion of cases. Despite decades of drug development, no LPS-neutralizing agent has achieved widespread clinical use — polymyxin B works but is nephrotoxic; monoclonal antibodies against LPS have failed in trials. Pleurocidin's combination of direct bactericidal activity plus LPS neutralization is therefore a genuinely novel mechanism.

Bhargava et al. (2013) in *Biochemistry* used isothermal titration calorimetry (ITC) and fluorescence spectroscopy to characterize Pleurocidin's LPS binding. The peptide bound LPS from *E. coli* O111:B4 with a Kd of approximately 0.3 µM — high-affinity binding that competes effectively with TLR4/MD-2 complex at physiologically relevant concentrations. In THP-1 monocyte cultures, 10 µg/mL Pleurocidin reduced LPS-stimulated IL-6 secretion by 72% and TNF-α by 68%, without significant cytotoxicity to the monocytes themselves.

Rao et al. (2018) extended this to a murine cecal ligation and puncture (CLP) model of polymicrobial sepsis — the gold standard preclinical sepsis model. Pleurocidin administered IP at 5 mg/kg at 1 hour post-CLP improved 72-hour survival from 30% (vehicle) to 65%. Plasma endotoxin levels were 58% lower in the Pleurocidin group, and IL-6, TNF-α, and IL-1β were all significantly reduced. Critically, bacterial CFU counts in peritoneal lavage fluid were also lower, confirming that the survival benefit came from both direct bactericidal activity and endotoxin neutralization — a dual mechanism that no conventional antibiotic provides.

Antifungal Activity

Cole et al.'s original 1997 paper noted antifungal activity against *Candida albicans* at 12.5 µg/mL. Subsequent work by Noga and colleagues confirmed activity against *C. albicans*, *C. glabrata*, and *Aspergillus fumigatus* at 12.5–50 µg/mL — higher than antibacterial MICs but still in a range relevant for topical or localized applications. The mechanism against fungi appears to involve disruption of the fungal plasma membrane (which, unlike mammalian membranes, contains ergosterol but still carries negative charge from phosphatidylserine and phosphatidylinositol). Antifungal activity is notably reduced at higher concentrations of ergosterol, suggesting that cholesterol/ergosterol content modulates sensitivity.

---

Complete Dosing Guide for Research Applications

*Note: Pleurocidin is a research peptide. All dosing information below is for in vitro and in vivo preclinical research only. No human clinical dosing has been established.*

Beginner Protocol (In Vitro Antimicrobial Screening)

For researchers new to working with Pleurocidin, the most straightforward entry point is MIC determination in bacterial culture.

Reconstitution: Dissolve lyophilized Pleurocidin in sterile 0.1% acetic acid to make a 1 mg/mL stock solution. Dilute to working concentrations in sterile phosphate-buffered saline (PBS) or Mueller-Hinton broth immediately before use. Avoid repeated freeze-thaw cycles; prepare single-use aliquots.

Storage: Lyophilized powder at –20°C, protected from moisture and light. Reconstituted stock at –80°C for up to 6 months; –20°C for up to 1 month. Working dilutions should be prepared fresh.

Standard Protocol (In Vivo Rodent Studies)

For murine infection or sepsis models, the literature supports the following parameters:

Bacterial infection models: IP or IV administration at 2–10 mg/kg, typically in sterile PBS vehicle. Given the short plasma half-life (~15–30 min), multiple dosing (every 4–6 hours) or continuous infusion via osmotic pump is used in longer-duration studies.

Sepsis/endotoxemia models: 5 mg/kg IP in the CLP model, administered at 1–2 hours post-procedure. Some groups use a 10 mg/kg loading dose followed by 5 mg/kg every 6 hours for 24–48 hours.

Tumor models (liposomal formulation): 10 mg/kg IP three times weekly, as used by Hilchie et al. (2019). Liposomal encapsulation is essential for systemic tumor models — free peptide is too rapidly cleared.

Topical wound models: 0.1–1% w/v in aqueous gel or saline irrigation, applied directly to wound surface. Concentrations in this range achieve local concentrations well above MIC while limiting systemic exposure.

Advanced Protocol (Analog and Combination Studies)

For researchers working with Pleurocidin analogs or combination regimens:

Synergy studies with antibiotics: Use checkerboard assays with Pleurocidin at ¼–½ × MIC combined with ciprofloxacin, vancomycin, or meropenem at ¼–½ × MIC. Calculate fractional inhibitory concentration index (FICI); values ≤0.5 indicate synergy.

D-amino acid analogs for protease resistance: D-Pleurocidin (all-D enantiomer) retains full antimicrobial activity but is completely resistant to trypsin and chymotrypsin. Use at the same concentrations as native L-Pleurocidin. D-Pleurocidin is the preferred form for in vivo studies where protease exposure is a concern.

NRC-07 analog for reduced hemolysis: NRC-07 (a designed analog with modified hydrophobic face) shows HC50 (hemolytic concentration 50%) >200 µg/mL vs. ~100 µg/mL for native Pleurocidin, with preserved MIC values. Use NRC-07 when hemolytic safety margins are critical to the study design.

---

Stacking Strategies for Research Applications

Stack 1: Pleurocidin + Conventional Antibiotic (Membrane Sensitization)

The most evidence-supported combination is Pleurocidin at sub-MIC concentrations paired with a conventional antibiotic. The rationale: Pleurocidin permeabilizes bacterial outer membranes, dramatically improving the uptake of hydrophilic antibiotics like aminoglycosides or fluoroquinolones that normally struggle to penetrate gram-negative outer membranes.

Mechanistic basis: Pleurocidin disrupts the LPS layer of gram-negative outer membranes (outer membrane permeabilization, OMP), reducing the barrier to antibiotic entry. This is similar to the mechanism of EDTA chelation of Mg²⁺ from LPS, but Pleurocidin achieves it without the toxicity and pH sensitivity of EDTA.

Combined dosing table:

This approach is particularly valuable for resistant strains where conventional antibiotic MICs are elevated. In MRSA studies, Pleurocidin at ½ MIC reduced the vancomycin MIC from 2 µg/mL to 0.25 µg/mL — an 8-fold potentiation.

Stack 2: Pleurocidin + LL-37 (Dual-AMP Broad-Spectrum)

LL-37 is the only human cathelicidin AMP, produced by neutrophils and epithelial cells. It has a distinct mechanism from Pleurocidin — LL-37 uses a carpet model at high concentrations and also has significant immunomodulatory activity via TLR signaling. Combining Pleurocidin (toroidal pore mechanism) with LL-37 (carpet mechanism) creates complementary membrane disruption strategies that are harder for bacteria to adapt to simultaneously.

Research rationale: Studies in the Hancock lab (University of British Columbia) demonstrated that AMP combinations with non-overlapping mechanisms often produce additive or synergistic effects with reduced resistance development. The Pleurocidin/LL-37 combination has not been extensively published as a formal stack, but the mechanistic logic is sound and several groups are exploring it.

Suggested research protocol:

Stack 3: Liposomal Pleurocidin + Cisplatin (Anticancer Research)

For researchers working in oncology, the combination of liposomal Pleurocidin with platinum-based chemotherapy offers a compelling research direction. The mechanistic basis comes from Yang et al.'s (2013) demonstration that Pleurocidin sensitizes ovarian cancer cells to cisplatin by disrupting membrane integrity, which may improve intracellular platinum accumulation.

Protocol:

---

Safety Deep Dive

Common Side Effects (In Vivo Research Context)

Hemolysis: Native Pleurocidin has an HC50 (concentration causing 50% lysis of human red blood cells) of approximately 100–125 µg/mL in standard assays. This gives a therapeutic index (HC50/MIC) of roughly 10–50:1 against bacterial targets — acceptable but not exceptional. At systemic doses used in murine models (5–10 mg/kg), hemolysis has not been reported as a significant finding, likely because free peptide is rapidly distributed and degraded before reaching hemolytic concentrations at erythrocytes.

Injection site reactions: IP and SC administration in rodents occasionally causes mild local inflammation, consistent with cationic peptide interaction with tissue mast cells and the mild pro-inflammatory activity of AMPs at high local concentrations.

Cytokine modulation: At high doses, Pleurocidin's LPS-binding activity and direct cell membrane interactions may transiently activate innate immune signaling. In the Rao et al. (2018) sepsis study, animals receiving 10 mg/kg showed a transient spike in IL-8-equivalent cytokines at 2 hours post-administration before overall cytokine levels normalized.

Rare/Theoretical Risks

Renal accumulation: Cationic peptides have a well-documented tendency to accumulate in proximal tubular cells of the kidney, where they can cause vacuolization and mild tubular toxicity at high doses. This is the mechanism behind polymyxin nephrotoxicity. Pleurocidin, with its lower positive charge (+2 vs. polymyxin's +5), shows significantly less renal accumulation, but researchers conducting repeat-dose studies should include kidney histology endpoints.

Immunogenicity: Like all non-human proteins and peptides, Pleurocidin has theoretical immunogenic potential in mammalian models. In practice, the short 25-residue length and relatively simple structure make it less immunogenic than larger proteins. No anti-Pleurocidin antibody responses have been reported in published rodent studies at doses up to 10 mg/kg × 3 weeks, but long-duration studies should include anti-peptide antibody monitoring.

Pro-aggregation at high concentrations: Above 50 µg/mL in low-salt buffers, Pleurocidin can self-aggregate, reducing effective free concentration and potentially confounding dose-response relationships. Always prepare dilutions in physiological-salt buffers (PBS, HBSS) at concentrations above 25 µg/mL and verify solubility visually.

Contraindications (Research Context)

---

Compared to Alternatives: Where Pleurocidin Fits in the AMP Landscape

The comparison tells a clear story. Pleurocidin occupies a middle ground: not as potent as Piscidin-1 against gram-negatives, but significantly less hemolytic. Not as immunomodulatory as LL-37, but with better-characterized membrane mechanics. Not as clinically available as polymyxin B, but without polymyxin's renal toxicity. Its unique value proposition is the combination of moderate potency + good safety margin + meaningful anticancer activity + strong LPS neutralization — a combination no single comparator matches.

For researchers specifically interested in marine AMPs, a comparison with LL-37 and the broader cathelicidin family is instructive. LL-37's immunomodulatory activity through TLR pathways gives it properties Pleurocidin lacks; conversely, Pleurocidin's cleaner membrane mechanism makes it easier to use as a mechanistic probe without confounding receptor-mediated effects.

---

Where to Buy Pleurocidin for Research

Pleurocidin is available from several specialty peptide suppliers as a research-grade synthetic peptide. When sourcing, prioritize suppliers who provide:

The C-terminal amide form (–NH₂) is the biologically relevant form matching the native sequence and should be specified when ordering. Some suppliers offer the free acid form (–OH); while this retains antimicrobial activity, the amide form is the standard for comparative research.

Expect to pay $80–$250 per 1 mg of Pleurocidin from reputable suppliers, depending on purity grade and supplier. For high-volume screening work, bulk pricing is available from several Chinese and North American custom synthesis houses at $30–$60 per mg at ≥95% purity.

NRC-03 and NRC-07 analogs are available from fewer suppliers and typically cost 20–40% more than native Pleurocidin due to more complex synthesis.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

What's Coming Next: The Future of Pleurocidin Research

The Pleurocidin field is moving in several exciting directions, and the unanswered questions are specific and tractable.

Resistance mechanism characterization: Despite Pleurocidin's reputation for slow resistance development, several research groups have observed that *P. aeruginosa* can develop 4–8-fold MIC increases after serial passage in sub-MIC Pleurocidin concentrations over 30 days. The mechanism appears to involve upregulation of the MexAB-OprM efflux pump and modifications to LPS lipid A acylation. Understanding these resistance pathways in detail will guide analog design to circumvent them — a research question with direct translational relevance.

Nanoparticle and hydrogel delivery systems: Multiple groups are developing Pleurocidin-loaded delivery systems for wound care applications. A 2022 preprint from Karolinska Institute described a chitosan-Pleurocidin hydrogel that maintained bactericidal activity over 72 hours in an ex vivo wound model, with significantly reduced cytotoxicity to keratinocytes compared to free peptide. If this work holds up in animal wound models, it could position Pleurocidin as a viable topical antimicrobial for chronic wound management — a $3.5 billion market currently dominated by silver-based dressings.

Anticancer mechanism refinement: The selectivity index of 3–5:1 for Pleurocidin's cancer cytotoxicity is real but modest. Current research is focused on understanding whether phosphatidylserine content alone explains cancer cell selectivity, or whether other membrane features (cholesterol content, membrane fluidity, surface charge density) contribute. If the selectivity determinants can be mapped, analog design to improve the therapeutic window becomes tractable. Two research groups are using lipidomic profiling of cancer vs. normal cells to build a predictive model for Pleurocidin sensitivity — work that would advance the entire membrane-active anticancer peptide field.

Human clinical development: No Pleurocidin derivative has entered human clinical trials as of 2025, but the NRC-03 and NRC-07 analogs have completed preclinical safety packages in rodents and are being positioned for IND-enabling studies. The most likely first indication is topical treatment of infected chronic wounds, where systemic exposure is minimal and the unmet need is large. A Phase I trial in this indication could realistically launch by 2027–2028 if current preclinical work continues to support the safety profile.

Synergy with innate immune peptides: The question of how Pleurocidin interacts with endogenous human AMPs in infected tissues remains incompletely characterized. Human skin and mucosa contain defensins, cathelicidins, and histatins that would co-localize with administered Pleurocidin. Whether these interactions are additive, synergistic, or antagonistic in complex biological environments is not yet known — and answering it requires ex vivo models with intact epithelial tissue, not just isolated bacteria in broth.

Biofilm penetration: Pleurocidin shows modest activity against preformed bacterial biofilms — considerably weaker than its planktonic MIC would predict, because the biofilm matrix (polysaccharides, DNA, proteins) sequesters cationic peptides before they reach bacteria. Research into PEGylated Pleurocidin derivatives, which resist matrix binding, is ongoing. The goal is biofilm MBEC (minimum biofilm eradication concentration) values within 4-fold of planktonic MIC — a threshold that would make Pleurocidin clinically viable for biofilm-associated infections like chronic wound infections, catheter-associated infections, and cystic fibrosis lung infections.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com